Latest Lipoprotein lipase Stories
A European Union agency for the evaluation of medicinal products is recommending the approval of a gene therapy treatment for a rare disease, which would be the first time a treatment of this kind has received the regulatory go-ahead for use in the West.
AMSTERDAM, July 7, 2011 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has filed a request for re-examination of the Marketing Authorisation Application for Glybera(R)with the European Medicines Agency.
AMSTERDAM, June 24, 2011 /PRNewswire/ -- - Dossier Re-Examination Process Initiated Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it has received an opinion on its Marketing Authorisation Application (MAA) for Glybera(R) (alipogene tiparvovec) as a potential therapy for Lipoprotein Lipase Deficiency ("LPLD").
AMSTERDAM, May 20, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today results from a long-term efficacy study of Glybera (alipogene tiparvovec) that showed improved chylomicron metabolism could be used as a biomarker for increased lipoprotein lipase (LPL) activity in those patients missing the gene that produces this protein.
- The parings of haberdine; also, any kind of fragments.